Valneva's 15-minute chart has triggered a narrowing of Bollinger Bands and a bearish Marubozu candlestick pattern on August 26, 2022 at 14:45. This indicates a decrease in the magnitude of stock price fluctuations, a dominance of sellers in the market, and a likelihood of continued bearish momentum.
Valneva SE (VALN) experienced a significant setback on Monday, August 25, 2025, as the United States Food and Drug Administration (FDA) suspended the license for its Chikungunya vaccine, Ixchiq. The suspension, effective immediately, requires Valneva to halt shipping and selling the vaccine in the United States. This development follows reports of four serious adverse events, including one death from encephalitis, attributed to the vaccine [1].
The FDA's decision has had a profound impact on Valneva's stock, with shares tumbling over 19% on Monday. Analysts have responded with mixed opinions. Jefferies analyst Maury Raycroft lowered Valneva's price target to $14 from $18 while maintaining a 'Buy' rating, citing potential risks for ex-U.S. regulators and the fact that Ixchiq is not a major revenue driver in the near term [1]. H.C. Wainwright analyst Brandon Folkes, however, reiterated a 'Buy' rating and kept an $18 price target, viewing the selloff as overdone and an attractive entry point for investors constructive on Valneva's investigational Lyme disease vaccine, VLA15 [1].
Valneva's stock has shown remarkable strength this year, up by 116% and 18% over the past 12 months, respectively. However, the FDA's decision has erased part of the 51% gain the stock had achieved in the previous 30 days. The suspension of Ixchiq's license is expected to have a minimal financial impact on the company in the short term, as Ixchiq contributed €7.5 million ($8.74 million) to the company’s €91 million total product sales in the first half of 2025 [1].
Valneva's 15-minute chart on August 26, 2025, at 14:45, triggered a narrowing of Bollinger Bands and a bearish Marubozu candlestick pattern, indicating a decrease in the magnitude of stock price fluctuations, a dominance of sellers in the market, and a likelihood of continued bearish momentum [2].
References:
[1] https://stocktwits.com/news-articles/markets/equity/valneva-stock-tumbles-after-us-fda-suspension-of-ixchiq-license/chssvsiRdSe
[2] https://www.investing.com/news/analyst-ratings/jefferies-lowers-valneva-stock-price-target-to-14-on-fda-suspension-93CH-4209311
Comments
No comments yet